Genotype-Guided Esketamine Dosing for Depression and Suicidality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for depression, particularly treatment-resistant depression and suicidality, are inadequate in providing timely and effective relief, and existing antidepressants may even increase suicidal ideation, necessitating a more personalized and efficient therapeutic approach.
Innovation Solution
Genotyping patients for the Val66Met rs6265 polymorphism in the BDNF gene to tailor the administration of esketamine, preferably intranasally, with specific dosing regimens for induction and maintenance phases based on genotype, differing in dosage and frequency for Val/Val, Val/Met, and Met/Met homozygotes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard antidepressant treatments are used for treatment-resistant depression, then some patients may experience relief, but many patients (40-50%) do not experience timely remission and some may even experience increased suicidal ideation
Solution Approach 1:
The patent performs genotyping for the Val66Met rs6265 polymorphism in the BDNF gene before initiating esketamine treatment. This preliminary genetic assessment allows clinicians to identify patients who are likely to respond to esketamine, enabling earlier intervention with an effective treatment rather than continuing with standard antidepressants that have failed or are unlikely to work, thereby reducing the time to remission.
2Ease of operation
If standardized dosing regimens are used for esketamine, then administration is simplified, but treatment efficacy is reduced for patients with different BDNF genotypes
Solution Approach 1:
The patent implements genotype-specific dosing regimens where Val/Val homozygotes receive 56 mg intranasally twice weekly, Val/Met heterozygotes receive 28 mg intranasally twice weekly, and Met/Met homozygotes receive 28 mg intranasally once weekly. This local customization of treatment quality based on individual genetic characteristics optimizes efficacy for each genotype group while maintaining clear, standardized protocols for each category.
3Reliability
If higher doses of esketamine are administered to ensure efficacy, then treatment effectiveness improves, but the risk of adverse effects and suicidal ideation increases
Solution Approach 1:
The patent changes the dosage parameter of esketamine based on the patient's BDNF genotype. Val/Val homozygotes receive higher doses (56 mg twice weekly) as they have better response profiles, while Val/Met heterozygotes and Met/Met homozygotes receive lower doses (28 mg twice weekly or once weekly respectively) to minimize adverse effects. This parameter optimization ensures adequate efficacy while reducing the risk of suicidal ideation in genotype groups that are more sensitive to esketamine's effects.
Data Source
AI summary
The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).